NASDAQ : ALKS
Alkermes plc — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Ireland
Last price 45.34 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 7.61B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.61B |
| Enterprise Value | 8.52B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 167.76M |
| Shares Outstanding | 167.76M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +4.38% |
| Owned by Insiders (%) | 1.49% |
| Owned by Institutions (%) | 103.24% |
| Float | 155.19M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 116.78 |
| Forward PE | 29.04 |
| PS Ratio | 4.56 |
| Forward PS | 4.05 |
| PB Ratio | 4.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 34.32 |
| P/OCF Ratio | 30.28 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 128.89 |
| EV / Sales | 5.11 |
| EV / EBITDA | 29.91 |
| EV / EBIT | 38.17 |
| EV / FCF | 38.45 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.30 |
| Quick Ratio | 1.68 |
| Debt / Equity | 0.87 |
| Debt / EBITDA | 5.28 |
| Debt / FCF | 7.09 |
| Interest Coverage | 3.78 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 3.85% |
| Return on Assets (ROA) | 4.20% |
| Return on Invested Capital (ROIC) | 5.47% |
| Return on Capital Employed (ROCE) | 5.98% |
| Weighted Average Cost of Capital (WACC) | 5.03% |
| Revenue Per Employee | $813,489 |
| Profits Per Employee | $32,255 |
| Employee Count | 2,050 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 0.87 |
Taxes
| Measure | Value |
|---|
| Income Tax | 31.20M |
| Effective Tax Rate | 32.06% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +44.17% |
| 50-Day Moving Average | 44.06 |
| 200-Day Moving Average | 40.48 |
| Relative Strength Index (RSI) | 61.13 |
| Average Volume (20 Days) | 1,880,499 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 19.05M |
| Short Previous Month | 17.82M |
| Short % of Shares Out | 11.35% |
| Short % of Float | 12.27% |
| Short Ratio (days to cover) | 7.67 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.67B |
| Gross Profit | 1.45B |
| Operating Income | 223.30M |
| Pretax Income | 97.32M |
| Net Income | 66.12M |
| EBITDA | 284.93M |
| EBIT | 223.30M |
| Earnings Per Share (EPS) | $0.39 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 656.58M |
| Total Debt | 1.57B |
| Net Cash | -915.99M |
| Net Cash Per Share | -$5.46 |
| Equity (Book Value) | 1.81B |
| Book Value Per Share | 10.79 |
| Working Capital | 860.82M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 251.18M |
| Capital Expenditures | -29.53M |
| Depreciation & Amortization | 61.63M |
| Net Borrowing | 1.50B |
| Free Cash Flow | 221.65M |
| FCF Per Share | $1.32 |
Margins
| Measure | Value |
|---|
| Gross Margin | 87.18% |
| Operating Margin | 13.39% |
| Pretax Margin | 5.84% |
| Profit Margin | 3.97% |
| EBITDA Margin | 17.09% |
| EBIT Margin | 13.39% |
| FCF Margin | 13.29% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.22% |
| Shareholder Yield | n/a |
| Earnings Yield | 0.86% |
| FCF Yield | 2.91% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $56.21 |
| Price Target Difference | 23.97% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | 12.76% |
| EPS Growth Forecast (3Y) | 4.78% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 15, 2000 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.76 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |